Bacterial coinfections and secondary infections in COVID-19 patients from a tertiary care hospital of northern India: Time to adhere to culture-based practices.
COVID-19
bacterial co-infection
secondary bacterial infections
Journal
Qatar medical journal
ISSN: 0253-8253
Titre abrégé: Qatar Med J
Pays: Qatar
ID NLM: 8101648
Informations de publication
Date de publication:
2021
2021
Historique:
received:
22
07
2021
accepted:
27
09
2021
entrez:
8
11
2021
pubmed:
9
11
2021
medline:
9
11
2021
Statut:
epublish
Résumé
Bacterial co-pathogens are common in various viral respiratory tract infections, leading to increased disease severity and mortality. Still, they are understudied during large outbreaks and pandemics. This study was conducted to highlight the overall burden of these infections in COVID-19 patients admitted to our tertiary care hospital, along with their antibiotic susceptibility patterns. During the six-month study period, clinical samples (blood samples, respiratory samples, and sterile body fluids, including cerebrospinal fluid [CSF]) of COVID-19 patients with suspected bacterial coinfections (at presentation) or secondary infections (after 48 hours of hospitalization) were received and processed for the same. Clinical samples of 814 COVID-19 patients were received for bacterial culture and susceptibility. Out of the total patient sample, 75% had already received empirical antibiotics before the samples were sent for analysis. Overall, 17.9% of cultures were positive for bacterial infections. Out of the total patients with bacterial infection, 74% (108/146) of patients had secondary bacterial infections (after 48 hours of hospitalization) and 26% (38/146) had bacterial coinfections (at the time of admission). Out of the 143 total isolates obtained, the majority (86%) were gram-negative organisms, of which The overall rate of secondary bacterial infections (SBIs) in our study was lower (7.9%) than reported by other studies. A rational approach would be to adhere to the practice of initiating culture-based guidance for antibiotics and to restrict unnecessary empirical antimicrobial therapy.
Identifiants
pubmed: 34745914
doi: 10.5339/qmj.2021.62
pii: qmj.2021.62
pmc: PMC8555674
doi:
Types de publication
Journal Article
Langues
eng
Pagination
62Informations de copyright
© 2021 Sharma, Sreenivasan, Biswal, Mahajan, Suri, Sehgal, Ray, Puri, Bhalla, Yaddanapudi, Koushal, Angrup, licensee HBKU Press.
Références
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
Clin Microbiol Infect. 2012 Mar;18(3):268-81
pubmed: 21793988
J Microbiol Immunol Infect. 2020 Aug;53(4):505-512
pubmed: 32482366
Front Microbiol. 2017 Jun 23;8:1041
pubmed: 28690590
J Infect Prev. 2021 May;22(3):119-125
pubmed: 34239610
Clin Microbiol Infect. 2020 Dec;26(12):1622-1629
pubmed: 32711058
J Immunol. 2013 Sep 1;191(5):2047-52
pubmed: 23964104
BMC Infect Dis. 2020 Sep 1;20(1):646
pubmed: 32873235
Virus Res. 2020 Aug;285:198005
pubmed: 32408156
Lancet. 2020 Feb 15;395(10223):470-473
pubmed: 31986257
Intensive Care Med. 2020 May;46(5):854-887
pubmed: 32222812
Clin Microbiol Infect. 2020 Jul;26(7):808-810
pubmed: 32360446
Int J Infect Dis. 2020 May;94:128-132
pubmed: 32251805
Indian J Med Microbiol. 2021 Apr;39(2):147-153
pubmed: 33966856
Clin Infect Dis. 2020 Dec 3;71(9):2459-2468
pubmed: 32358954
Clin Microbiol Infect. 2020 Oct;26(10):1395-1399
pubmed: 32603803
Curr Opin Infect Dis. 2004 Jun;17(3):185-91
pubmed: 15166819
Antimicrob Resist Infect Control. 2020 Sep 22;9(1):153
pubmed: 32962731